GlassScriptPhysician profile
Kyle A Nedic
NPI 1538519988
$2,185.92
in general payments reported to CMS, 2019-2025
29 companies · $2,040 in 2025
The $2,040 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.37 · 2024: $94.26 · 2025: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,134.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $398.67 | 2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $261.56 | 2024-2025 | |
| Novo Nordisk INC | $215.48 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $175.40 | 2025 | Mounjaro, Jardiance, Zepbound |
| Vanda Pharmaceuticals INC. | $142.16 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.66 | 2024-2025 | Xifaxan |
| Pfizer INC. | $57.58 | 2025 | |
| Biogen, INC. | $53.79 | 2025 | Skyclarys, Spinraza |
| Corcept Therapeutics | $51.50 | 2025 | Korlym |
| Csl Behring | $51.37 | 2019 | |
| Glaxosmithkline, LLC. | $50.75 | 2025 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $50.67 | 2025 | Nexletol |
| Exact Sciences Corporation | $50.52 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $48.55 | 2025 | Veozah |
| Amgen INC. | $45.00 | 2025 | Repatha, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $43.76 | 2025 | Xyosted |
| Grifols USA, LLC | $43.37 | 2025 | Prolastin-C Liquid |
| Qol Medical, LLC | $36.70 | 2025 | Sucraid |
| Seqirus USA INC | $33.50 | 2024-2025 | Flucelvax, Fluad |
| Axsome Therapeutics, INC. | $32.57 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $29.12 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.02 | 2025 | Caplyta |
| Alkermes, INC. | $28.93 | 2025 | Vivitrol |
| Verity Pharmaceuticals INC. | $28.26 | 2025 | Tlando |
| Ani Pharmaceuticals, INC. | $25.00 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.55 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $23.30 | 2025 | |
| Dexcom, INC. | $20.06 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $18.12 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Nedic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.